Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

716
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
716
Inflammation01:38

Inflammation

61.3K
Overview
61.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

285
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

403
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
403
T Cell Types and Functions01:24

T Cell Types and Functions

2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

822
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
822

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting inflammatory and angiogenic responses by small-molecule kinase inhibitors in a 3D macrophage-containing spheroid model of rheumatoid arthritis synovial tissue.

Arthritis research & therapy·2026
Same author

Transcriptional and chromatin dynamics in macrophage differentiation and activation.

Science immunology·2026
Same author

Rational use of expensive medicines in the Netherlands: strategies to improve effectiveness and reduce burden on patients and society - a narrative review.

BMC medicine·2026
Same author

Female-Biased VSMC GRNs Predict MYH9 as Regulator of Fibrous Plaque Phenotype.

Circulation research·2026
Same author

Transfer of IgG from long COVID patients induces symptomology in mice.

Cell reports. Medicine·2026
Same author

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.

European journal of immunology·2026
Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.8K

Type-I interferons in atherosclerosis.

Hung-Jen Chen1, Sander W Tas2, Menno P J de Winther1,3

  • 1Experimental Vascular Biology, Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

The Journal of Experimental Medicine
|December 11, 2019
PubMed
Summary
This summary is machine-generated.

Type-I interferons (IFNs) drive atherosclerosis by impacting immune cells and blood vessels. Targeting these inflammatory signals offers new strategies for preventing and treating cardiovascular diseases (CVDs).

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.7K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.1K

Related Experiment Videos

Last Updated: Jan 2, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.8K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.7K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.1K

Area of Science:

  • Immunology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Dyslipidemia and inflammation are key contributors to atherosclerosis.
  • Emerging evidence links type-I interferons (IFNs) to cardiovascular disease (CVD) pathogenesis.
  • Autoimmune diseases with accelerated atherosclerosis highlight inflammation's role in CVD.

Purpose of the Study:

  • To review the role of type-I IFNs in atherosclerosis.
  • To discuss the molecular mechanisms by which type-I IFNs affect cardiovascular health.
  • To explore therapeutic strategies targeting type-I IFN signaling for CVD prevention and treatment.

Main Methods:

  • Review of molecular biology studies.
  • Analysis of animal models of atherosclerosis.
  • Examination of clinical observations and patient data.

Main Results:

  • Type-I IFNs influence plaque-residing macrophages, foam cell formation, and extracellular trap release.
  • Type-I IFNs induce endothelial dysfunction and alter immune cell phenotypes (dendritic cells, T cells, B cells).
  • Elevated serum type-I IFN levels correlate with increased CVD incidence.

Conclusions:

  • Type-I IFNs play a significant role in exacerbating atherosclerosis.
  • Targeting type-I IFN signaling presents a promising therapeutic avenue for cardiovascular diseases.
  • Further research into anti-IFN therapies could revolutionize CVD treatment.